Oncolytics Biotech Inc. Common Stock (ONCY)
Stock · NASDAQ · Health Care
$0.8457as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$0.793375
Industry
Biotechnology: Pharmaceutical Preparations
About ONCY
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply i…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 29
- Website
- www.oncolyticsbiotech.com/
Fundamentals
- 1-day range
- $0.8207$0.8599
- Market cap
- $95.55M
- P/E (trailing)
- —
- P/E (forward)
- -3.53
- EPS (trailing)
- $-0.37
- Dividend yield
- —
- Beta
- 0.84
- Avg. volume
- 1.28M
- Dividend pay date
- May 25, 2018
52-week range
$1.39$1.44
Next earnings: November 16, 2026 · EPS estimate $-0.08
Forecasts
6 analyst ratings
Buy 75%
Hold 25%
Sell 0%
1-year price forecast
High
$6.06
+616.5%
Median
$4.25
+402.2%
Low
$2.91
+244.6%
Oncolytics Biotech Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ONCYOncolytics Biotech Inc. Common Stock$0.8457▼ 0.51%Market cap $95.55MP/E —$1.39$1.44
- ALDXAldeyra Therapeutics Inc. Common Stock$1.49▼ 3.57%Market cap $95.91MP/E —$1.07$6.18
- RANIRani Therapeutics Holdings Inc. Class A Common Stock$0.845▼ 1.05%Market cap $96.76MP/E —$0.44$3.87
- VRCAVerrica Pharmaceuticals Inc. Common Stock$5.54▲ 9.27%Market cap $92.08MP/E —$3.28$9.82
- FBIOFortress Biotech Inc. Common Stock$2.77▼ 1.07%Market cap $92.02MP/E 0.75$2.18$4.53
- NTHINeOnc Technologies Holdings Inc. Common Stock$4.69▲ 1.74%Market cap $90.77MP/E —$3.01$12.99
- MAIAMAIA Biotechnology Inc. Common Stock$1.33▼ 3.99%Market cap $86.34MP/E —$0.87$3.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ONCY Oncolytics Biotech Inc. Common Stock | $95.55M | — | $0.8457 | ▼ 0.51% | $1.39$1.44 |
| ALDX Aldeyra Therapeutics Inc. Common Stock | $95.91M | — | $1.49 | ▼ 3.57% | $1.07$6.18 |
| RANI Rani Therapeutics Holdings Inc. Class A Common Stock | $96.76M | — | $0.845 | ▼ 1.05% | $0.44$3.87 |
| VRCA Verrica Pharmaceuticals Inc. Common Stock | $92.08M | — | $5.54 | ▲ 9.27% | $3.28$9.82 |
| FBIO Fortress Biotech Inc. Common Stock | $92.02M | 0.75 | $2.77 | ▼ 1.07% | $2.18$4.53 |
| NTHI NeOnc Technologies Holdings Inc. Common Stock | $90.77M | — | $4.69 | ▲ 1.74% | $3.01$12.99 |
| MAIA MAIA Biotechnology Inc. Common Stock | $86.34M | — | $1.33 | ▼ 3.99% | $0.87$3.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5benzinga · 8/19/2026
- HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5Benzinga · 8/19/2026
- Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer TrialsYahoo · 8/19/2026
- Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal CancerYahoo · 8/18/2026
- Oncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study DesignBenzinga · 8/18/2026
Insider Activity
Insider Actions →Acquired
2.25M
Disposed
0
- McAdory John Bearden · June 1, 2026 · Grant145.0K
- Stephen C. Glover · June 1, 2026 · Grant96.0K
- Deborah Margaret Brown · June 1, 2026 · Grant30.0K
- RIGBY JONATHAN · June 1, 2026 · Grant30.0K
- Wayne Pisano · June 1, 2026 · Grant30.0K
- Holtham Angela · June 1, 2026 · Grant30.0K
- Kirk Look · June 1, 2026 · Grant260.0K
- James T. Parsons · June 1, 2026 · Grant30.0K
- Andrew Aromando · June 1, 2026 · Grant260.0K
- Jared Kelly · June 1, 2026 · Grant755.0K
- Patricia S. Andrews · June 1, 2026 · Grant30.0K
- Bernd R. Seizinger · June 1, 2026 · Grant30.0K
- Allison Hagerman · June 1, 2026 · Grant260.0K
- Thomas Charles Heineman · June 1, 2026 · Grant260.0K
- Jared Kelly · March 12, 2026 · Buy5.0K @ $0.96
Institutional Ownership
March 31, 2026
- Total shares held
- 860.0K
- Total value held
- $731.0K
- Institutional holders
- 2
Top holders this quarter
- Unknown859.8K
- Unknown194
See the full, filterable feed with live charts on the MarketWall dashboard.